stockrowLexeo Therapeutics, Inc.
LXEOLexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00.
- EPS
- +50.0%
- Free cash flow
- +35.6%
- Total debt
- −83.5%
Quarter to June 2026, against a year earlier
Follow LXEO
Alert me
Lexeo Therapeutics, Inc. (LXEO) Return on invested capital
Lexeo Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −253.5%, down 148.8 percentage points from fiscal 2025 (−104.7%). Over the past ten years it has ranged from −104.7% (fiscal 2025) to 0.00% (fiscal 2024) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −104.7% | (104.69) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LRMR Larimar Therapeutics, Inc. compare | 0.00% |
| CAMP CAMP4 Therapeutics Corporation compare | 0.00% |
| ABEO Abeona Therapeutics Inc. compare | 0.00% |
| FATE Fate Therapeutics, Inc. compare | 0.00% |
| EVMN Evommune Inc. compare | −82.5% |
| LCTX Lineage Cell Therapeutics, Inc. compare | −186.8% |
| IMRX Immuneering Corporation compare | −198.4% |
| LXEO Lexeo Therapeutics, Inc. | −253.5% |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)